Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
Citi
Accenture
Chubb
McKinsey
Deloitte
Healthtrust
Fuji

Generated: February 20, 2019

DrugPatentWatch Database Preview

SIMULECT Drug Profile

« Back to Dashboard

Summary for Tradename: SIMULECT
Patents:96
Applicants:1
BLAs:1
Suppliers: see list1

US Patents for SIMULECT

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Try a Free Trial UNIVERSITY OF WYOMING (Laramie, WY) ➤ Try a Free Trial RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Try a Free Trial AiCuris GmbH & Co. KG (Wuppertal, DE) ➤ Try a Free Trial RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Try a Free Trial CureVac AG (Tubingen, DE) ➤ Try a Free Trial RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Try a Free Trial Universitatsklinikum Freiburg (Freiburg, DE) Medizinische Universitat Wien (Vienna, AT) ➤ Try a Free Trial RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Try a Free Trial University of Maryland, Baltimore (Baltimore, MD) The United States of America as Represented by the Department of Veteran Affairs (Washington, DC) ➤ Try a Free Trial RX search
Novartis SIMULECT basiliximab VIAL; SINGLE-USE 103764 001 1998-05-12 ➤ Try a Free Trial Advanced Bionics Corporation (Valencia, CA) ➤ Try a Free Trial RX search
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for SIMULECT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
11C0053 France ➤ Try a Free Trial PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001-002 20110617
PA2011014,C1248802 Lithuania ➤ Try a Free Trial PRODUCT NAME: BELATACEPTUM; REGISTRATION NO/DATE: EU/1/11/694/001, 2011 06 17 EU/1/11/694/002 20110617
92780 Luxembourg ➤ Try a Free Trial PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826
91902 Luxembourg ➤ Try a Free Trial 91902, EXPIRES: 20260523
C300509 Netherlands ➤ Try a Free Trial PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001 - 002 20110617
122011100063 Germany ➤ Try a Free Trial PRODUCT NAME: BELATACEPT; REGISTRATION NO/DATE: EU/1/11/694/001-002 20110617
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Farmers Insurance
US Department of Justice
Boehringer Ingelheim
Merck
Chinese Patent Office
Accenture
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.